Dr Mark Bleackley: New Medication to Benefit Patients With Obstructive Sleep Apnea Kyle Munz Mark Bleackley, PhD, chief scientific officer, Incannex, details the progress of the ongoing RePOSA trial, which is assessing the safety and efficacy of IHL-42X in patients with obstructive sleep apnea (...
Anthropometric measurements, obstructive sleep apnea103 Anti-kickback regulations26–27 Apnea hypopnea index (AHI)101,102,204 Apneas176 Application, consumer sleep technology209 Artifacts172 ASV. see Adaptive-servoventilation (ASV) ASWPD. see Advanced sleep-wake phase disorder (ASWPD) Asynchronous appoin...
sleep duration, and heart disease risk. Previous studies regarding sex differences in sleep and heart disease are inconsistent and findings differ by specific sleep dimensions. For example, men are more likely to have an earlier onset of obstructive sleep apnea,...